| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥17.91B | ¥20.21B | -11.4% |
| Cost of Sales | ¥10.71B | ¥9.49B | +12.8% |
| Gross Profit | ¥7.20B | ¥10.72B | -32.8% |
| SG&A Expenses | ¥7.76B | ¥8.18B | -5.2% |
| Operating Income | ¥-557M | ¥2.54B | -122.0% |
| Non-operating Income | ¥1.10B | ¥332M | +231.3% |
| Non-operating Expenses | ¥11M | ¥516M | -97.9% |
| Ordinary Income | ¥531M | ¥2.35B | -77.4% |
| Profit Before Tax | ¥361M | ¥2.35B | -84.7% |
| Income Tax Expense | ¥131M | ¥422M | -69.0% |
| Net Income | ¥229M | ¥1.93B | -88.1% |
| Net Income Attributable to Owners | ¥229M | ¥1.93B | -88.1% |
| Total Comprehensive Income | ¥-140M | ¥3.70B | -103.8% |
| Interest Expense | ¥2M | ¥2M | +0.0% |
| Basic EPS | ¥4.21 | ¥35.39 | -88.1% |
| Dividend Per Share | ¥15.00 | ¥15.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥37.80B | ¥39.63B | ¥-1.83B |
| Cash and Deposits | ¥9.12B | ¥15.13B | ¥-6.01B |
| Accounts Receivable | ¥8.08B | ¥7.19B | +¥884M |
| Inventories | ¥2.99B | ¥3.40B | ¥-404M |
| Non-current Assets | ¥44.13B | ¥44.24B | ¥-115M |
| Item | Value |
|---|---|
| Net Profit Margin | 1.3% |
| Gross Profit Margin | 40.2% |
| Current Ratio | 574.7% |
| Quick Ratio | 529.2% |
| Debt-to-Equity Ratio | 0.13x |
| Interest Coverage Ratio | -278.50x |
| Effective Tax Rate | 36.3% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | -11.4% |
| Operating Income YoY Change | +71.2% |
| Ordinary Income YoY Change | -77.4% |
| Net Income Attributable to Owners YoY Change | -88.1% |
| Total Comprehensive Income YoY Change | -26.3% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 56.81M shares |
| Treasury Stock | 2.21M shares |
| Average Shares Outstanding | 54.59M shares |
| Book Value Per Share | ¥1,323.06 |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥15.00 |
| Year-End Dividend | ¥15.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| LAL | ¥5.78B | ¥178M |
| Pharmaceutical | ¥12.13B | ¥-735M |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥35.60B |
| Operating Income Forecast | ¥-300M |
| Ordinary Income Forecast | ¥1.35B |
| Net Income Attributable to Owners Forecast | ¥1.35B |
| Basic EPS Forecast | ¥24.74 |
| Dividend Per Share Forecast | ¥15.00 |
| Property, Plant & Equipment | ¥20.45B | ¥18.45B | +¥2.00B |
| Intangible Assets | ¥2.80B | ¥3.15B | ¥-347M |
| Goodwill | ¥1.80B | ¥1.97B | ¥-165M |
| Investment Securities | ¥17.09B | ¥19.04B | ¥-1.95B |
| Total Assets | ¥81.93B | ¥83.87B | ¥-1.94B |
| Current Liabilities | ¥6.58B | ¥7.90B | ¥-1.32B |
| Accounts Payable | ¥1.20B | ¥991M | +¥210M |
| Short-term Loans | ¥300M | ¥300M | ¥0 |
| Non-current Liabilities | ¥3.11B | ¥2.79B | +¥321M |
| Total Liabilities | ¥9.69B | ¥10.69B | ¥-1.00B |
| Total Equity | ¥72.24B | ¥73.19B | ¥-944M |
| Capital Stock | ¥3.84B | ¥3.84B | ¥0 |
| Capital Surplus | ¥5.30B | ¥5.30B | ¥0 |
| Retained Earnings | ¥53.82B | ¥54.42B | ¥-598M |
| Treasury Stock | ¥-2.22B | ¥-2.24B | +¥25M |
| Owners' Equity | ¥72.24B | ¥73.19B | ¥-944M |
| Working Capital | ¥31.22B | - | - |